- Home
- CINT vs REPL Comparison
CINT vs REPL Comparison
Compare CINT & REPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CINT
- REPL
- Stock Information
- Founded
- CINT 1995
- REPL 2015
- Country
- CINT Brazil
- REPL United States
- Employees
- CINT N/A
- REPL N/A
- Industry
- CINT EDP Services
- REPL Biotechnology: Pharmaceutical Preparations
- Sector
- CINT Technology
- REPL Health Care
- Exchange
- CINT Nasdaq
- REPL Nasdaq
- Market Cap
- CINT 803.4M
- REPL 757.8M
- IPO Year
- CINT 2021
- REPL 2018
- Fundamental
- Price
- CINT $5.57
- REPL $12.24
- Analyst Decision
- CINT Buy
- REPL Strong Buy
- Analyst Count
- CINT 7
- REPL 7
- Target Price
- CINT $7.61
- REPL $21.00
- AVG Volume (30 Days)
- CINT 87.5K
- REPL 1.9M
- Earning Date
- CINT 08-15-2025
- REPL 08-07-2025
- Dividend Yield
- CINT N/A
- REPL N/A
- EPS Growth
- CINT 53.80
- REPL N/A
- EPS
- CINT 0.24
- REPL N/A
- Revenue
- CINT $444,135,000.00
- REPL N/A
- Revenue This Year
- CINT $521.47
- REPL N/A
- Revenue Next Year
- CINT $13.05
- REPL N/A
- P/E Ratio
- CINT $22.96
- REPL N/A
- Revenue Growth
- CINT 3.04
- REPL N/A
- 52 Week Low
- CINT $4.42
- REPL $6.44
- 52 Week High
- CINT $8.04
- REPL $17.00
- Technical
- Relative Strength Index (RSI)
- CINT 43.06
- REPL 73.41
- Support Level
- CINT $5.89
- REPL $9.26
- Resistance Level
- CINT $5.94
- REPL $13.19
- Average True Range (ATR)
- CINT 0.17
- REPL 0.68
- MACD
- CINT -0.03
- REPL 0.29
- Stochastic Oscillator
- CINT 23.33
- REPL 80.10
About CINT CI&T Inc
CI&T Inc is engaged in providing strategy, design, and software engineering services to enable digital transformation for companies. The company mainly develops customizable software through the implementation of several software solutions, including Machine Learning, Artificial Intelligence (AI), Analytics, Cloud, and Mobility technologies. The majority of the revenue is generated from the North America and Europe, followed by Asia, Pacific and Japan.
About REPL Replimune Group Inc.
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.